| Accession |
PRJCA013169 |
| Title |
Proteogenomics of Clear Cell Renal Cell Carcinoma Response to Tyrosine Kinase Inhibitor |
| Relevance |
Medical |
| Data types |
Transcriptome or Gene expression
|
| Organisms |
Homo sapiens
|
| Description |
Integrated proteogenomic characterization of 115 tumors from patients with clear cell renal cell carcinoma (ccRCC) undergoing Sunitinib treatment in Chinese population revealed the molecular basis of differential clinical outcomes with tyrosine kinase inhibitor (TKI) therapy. We found that chromosome 7q gain-induced mTOR signaling activation was associated with poor therapeutic outcomes with Sunitinib treatment, whereas the aristolochic acid signature and VHL mutation synergistically caused enhanced glycolysis was correlated with better prognosis. The proteomic and phosphoproteomic analysis further highlighted the responsibility of mTOR signaling for non-response to Sunitinib. Immune landscape characterization revealed diverse tumor microenvironment subsets in ccRCC, among which the progenitor-infiltrated group manifested upregulated platelet aggregation and poor prognosis to therapy. To better direct the selection of treatment, we constructed a proteomic classifier and verified its robustness in an independent dataset. Overall, our proteogenomic analyses revealed associations between ccRCC molecular characteristics and the response to TKI, which can facilitate future improvement of therapeutic responses. |
| Sample scope |
Monoisolate |
| Release date |
2023-06-13 |
| Publication |
| PubMed ID |
Article title |
Journal name |
DOI |
Year |
| 37460463
|
Proteogenomics of clear cell renal cell carcinoma response to tyrosine kinase inhibitor
|
Nature Communications
|
10.1038/s41467-023-39981-6
|
2023
|
|
|
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| National Natural Science Foundation of China (NSFC)
|
Key Program
|
2019YFA0801900
|
|
|
|
| Submitter |
Chen
Ding (chend@fudan.edu.cn)
|
| Organization |
Fudan University |
| Submission date |
2022-11-12 |
